These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1848 related articles for article (PubMed ID: 9141536)

  • 1. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.
    Khorram O; Yeung M; Vu L; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3590-6. PubMed ID: 9360512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
    Morales AJ; Nolan JJ; Nelson JC; Yen SS
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1360-7. PubMed ID: 7515387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
    Vittone J; Blackman MR; Busby-Whitehead J; Tsiao C; Stewart KJ; Tobin J; Stevens T; Bellantoni MF; Rogers MA; Baumann G; Roth J; Harman SM; Spencer RG
    Metabolism; 1997 Jan; 46(1):89-96. PubMed ID: 9005976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
    Bellantoni MF; Vittone J; Campfield AT; Bass KM; Harman SM; Blackman MR
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
    Gentili A; Mulligan T; Godschalk M; Clore J; Patrie J; Iranmanesh A; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Feb; 87(2):825-34. PubMed ID: 11836328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
    Gill MS; Toogood AA; Jones J; Clayton PE; Shalet SM
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
    Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea.
    Laughlin GA; Dominguez CE; Yen SS
    J Clin Endocrinol Metab; 1998 Jan; 83(1):25-32. PubMed ID: 9435412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults.
    Laursen T; Gravholt CH; Heickendorff L; Drustrup J; Kappelgaard AM; Jørgensen JO; Christiansen JS
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1222-8. PubMed ID: 11238512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.
    Münzer T; Rosen CJ; Harman SM; Pabst KM; St Clair C; Sorkin JD; Blackman MR
    Am J Physiol Endocrinol Metab; 2006 May; 290(5):E1006-13. PubMed ID: 16390864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.